These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

139 related articles for article (PubMed ID: 25018036)

  • 1. A multigene assay identifying distinct prognostic subtypes of clear cell renal cell carcinoma with differential response to tyrosine kinase inhibition.
    Choudhury Y; Wei X; Chu YH; Ng LG; Tan HS; Koh V; Thike AA; Poon E; Ng QS; Toh CK; Kanesvaran R; Tan PH; Tan MH
    Eur Urol; 2015 Jan; 67(1):17-20. PubMed ID: 25018036
    [TBL] [Abstract][Full Text] [Related]  

  • 2. ClearCode34: A prognostic risk predictor for localized clear cell renal cell carcinoma.
    Brooks SA; Brannon AR; Parker JS; Fisher JC; Sen O; Kattan MW; Hakimi AA; Hsieh JJ; Choueiri TK; Tamboli P; Maranchie JK; Hinds P; Miller CR; Nielsen ME; Rathmell WK
    Eur Urol; 2014 Jul; 66(1):77-84. PubMed ID: 24613583
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Molecular subtypes of clear cell renal cell carcinoma are associated with sunitinib response in the metastatic setting.
    Beuselinck B; Job S; Becht E; Karadimou A; Verkarre V; Couchy G; Giraldo N; Rioux-Leclercq N; Molinié V; Sibony M; Elaidi R; Teghom C; Patard JJ; Méjean A; Fridman WH; Sautès-Fridman C; de Reyniès A; Oudard S; Zucman-Rossi J
    Clin Cancer Res; 2015 Mar; 21(6):1329-39. PubMed ID: 25583177
    [TBL] [Abstract][Full Text] [Related]  

  • 4. MicroRNAs with prognostic potential for metastasis in clear cell renal cell carcinoma: a comparison of primary tumors and distant metastases.
    Heinzelmann J; Unrein A; Wickmann U; Baumgart S; Stapf M; Szendroi A; Grimm MO; Gajda MR; Wunderlich H; Junker K
    Ann Surg Oncol; 2014 Mar; 21(3):1046-54. PubMed ID: 24242678
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Integrated genomic analysis identifies clinically relevant subtypes of renal clear cell carcinoma.
    Wu P; Liu JL; Pei SM; Wu CP; Yang K; Wang SP; Wu S
    BMC Cancer; 2018 Mar; 18(1):287. PubMed ID: 29534679
    [TBL] [Abstract][Full Text] [Related]  

  • 6. MiR-99b-5p expression and response to tyrosine kinase inhibitor treatment in clear cell renal cell carcinoma patients.
    Lukamowicz-Rajska M; Mittmann C; Prummer M; Zhong Q; Bedke J; Hennenlotter J; Stenzl A; Mischo A; Bihr S; Schmidinger M; Vogl U; Blume I; Karlo C; Schraml P; Moch H
    Oncotarget; 2016 Nov; 7(48):78433-78447. PubMed ID: 27738339
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Metabolic and Lipidomic Reprogramming in Renal Cell Carcinoma Subtypes Reflects Regions of Tumor Origin.
    Schaeffeler E; Büttner F; Reustle A; Klumpp V; Winter S; Rausch S; Fisel P; Hennenlotter J; Kruck S; Stenzl A; Wahrheit J; Sonntag D; Scharpf M; Fend F; Agaimy A; Hartmann A; Bedke J; Schwab M
    Eur Urol Focus; 2019 Jul; 5(4):608-618. PubMed ID: 29452772
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Identification of a 6-Gene Signature Associated with Resistance to Tyrosine Kinase Inhibitors: Prognosis for Clear Cell Renal Cell Carcinoma.
    Li Q; Yang W; Lu M; Zhang R
    Med Sci Monit; 2020 Dec; 26():e927078. PubMed ID: 33296352
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Prognostic factors in second-line targeted therapy for metastatic clear-cell renal cell carcinoma after progression on an anti-vascular endothelial growth factor receptor tyrosine kinase inhibitor.
    Sacré A; Barthélémy P; Korenbaum C; Burgy M; Wolter P; Dumez H; Lerut E; Loyson T; Joniau S; Oyen R; Debruyne PR; Schöffski P; Beuselinck B
    Acta Oncol; 2016; 55(3):329-40. PubMed ID: 26494607
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Molecular Subtypes of Clear Cell Renal Cell Carcinoma Are Associated With Outcome During Pazopanib Therapy in the Metastatic Setting.
    Verbiest A; Couchy G; Job S; Zucman-Rossi J; Caruana L; Lerut E; Oyen R; de Reyniès A; Laguerre B; Rioux-Leclercq N; Wozniak A; Joniau S; Van Poppel H; Van Den Eynde K; Beuselinck B
    Clin Genitourin Cancer; 2018 Jun; 16(3):e605-e612. PubMed ID: 29239846
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Fatty acid binding protein 7 may be a marker and therapeutic targets in clear cell renal cell carcinoma.
    Nagao K; Shinohara N; Smit F; de Weijert M; Jannink S; Owada Y; Mulders P; Oosterwijk E; Matsuyama H
    BMC Cancer; 2018 Nov; 18(1):1114. PubMed ID: 30442117
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Molecular Subtypes of Clear-cell Renal Cell Carcinoma are Prognostic for Outcome After Complete Metastasectomy.
    Verbiest A; Couchy G; Job S; Caruana L; Lerut E; Oyen R; de Reyniès A; Tosco L; Joniau S; Van Poppel H; Van Raemdonck D; Van Den Eynde K; Wozniak A; Zucman-Rossi J; Beuselinck B
    Eur Urol; 2018 Oct; 74(4):474-480. PubMed ID: 29463434
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Identification of subtype specific biomarkers of clear cell renal cell carcinoma using random forest and greedy algorithm.
    Wu Y; Han W; Xu D; Wang X; Yang J; Lu Z; Chen X; Ding Y
    Biosystems; 2021 Jun; 204():104372. PubMed ID: 33582210
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The Association Between PD-L1 Expression and the Clinical Outcomes to Vascular Endothelial Growth Factor-Targeted Therapy in Patients With Metastatic Clear Cell Renal Cell Carcinoma.
    Shin SJ; Jeon YK; Cho YM; Lee JL; Chung DH; Park JY; Go H
    Oncologist; 2015 Nov; 20(11):1253-60. PubMed ID: 26424759
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Patients with ClearCode34-identified molecular subtypes of clear cell renal cell carcinoma represent unique populations with distinct comorbidities.
    Haake SM; Brooks SA; Welsh E; Fulp WJ; Chen DT; Dhillon J; Haura E; Sexton W; Spiess PE; Pow-Sang J; Rathmell WK; Fishman M
    Urol Oncol; 2016 Mar; 34(3):122.e1-7. PubMed ID: 26546482
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Sarcomatoid features, necrosis, and grade are prognostic factors in metastatic clear cell renal cell carcinoma with vascular endothelial growth factor-targeted therapy.
    Park JY; Lee JL; Baek S; Eo SH; Go H; Ro JY; Cho YM
    Hum Pathol; 2014 Jul; 45(7):1437-44. PubMed ID: 24784922
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Clinical utility of the S3-score for molecular prediction of outcome in non-metastatic and metastatic clear cell renal cell carcinoma.
    Büttner F; Winter S; Rausch S; Hennenlotter J; Kruck S; Stenzl A; Scharpf M; Fend F; Agaimy A; Hartmann A; Bedke J; Schwab M; Schaeffeler E
    BMC Med; 2018 Jul; 16(1):108. PubMed ID: 29973214
    [TBL] [Abstract][Full Text] [Related]  

  • 18. FOXC2 and CLIP4 : a potential biomarker for synchronous metastasis of ≤7-cm clear cell renal cell carcinomas.
    Ahn J; Han KS; Heo JH; Bang D; Kang YH; Jin HA; Hong SJ; Lee JH; Ham WS
    Oncotarget; 2016 Aug; 7(32):51423-51434. PubMed ID: 27283491
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Clear cell renal cell carcinoma: gene expression analyses identify a potential signature for tumor aggressiveness.
    Kosari F; Parker AS; Kube DM; Lohse CM; Leibovich BC; Blute ML; Cheville JC; Vasmatzis G
    Clin Cancer Res; 2005 Jul; 11(14):5128-39. PubMed ID: 16033827
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Development and confirmation of potential gene classifiers of human clear cell renal cell carcinoma using next-generation RNA sequencing.
    Eikrem OS; Strauss P; Beisland C; Scherer A; Landolt L; Flatberg A; Leh S; Beisvag V; Skogstrand T; Hjelle K; Shresta A; Marti HP
    Scand J Urol; 2016 Dec; 50(6):452-462. PubMed ID: 27739342
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.